Investor Relations


We intend to continue our business development effort by adding other proven domestic and international biotechnology partners to monetize the China health care market

  • Dec 5, 2020
    ASH 2020, United States

    An Anti-BCMA CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma

  • Aug 30, 2020
    Rockville, MD

    25th Annual Conference of the Chinese Biopharmaceutical Association-USA (CBA)

  • Jul 13, 2020
    Gaithersburg, MD

    CBMG R&D Showcase and Updates to Clinical Programs